Back to News
Market Impact: 0.3
FDA Clears New Manufacturing Process For Alvotech's SIMLANDI Biosimilar; Stock Up
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
The U.S. FDA approved Alvotech's upgraded manufacturing process for SIMLANDI (adalimumab-ryvk), its Humira biosimilar, allowing production with the process at the company's Reykjavik, Iceland facility. The article provides no financial figures or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ALVO0.70
More News
- Morgan Stanley initiates ADARx stock with overweight rating
- FDA approves new manufacturing process for Alvotech biosimilar
- Jio’s Record $3.2 Billion IPO Puts India’s Market Muscle to the Test
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas